184 related articles for article (PubMed ID: 28887213)
1. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
[TBL] [Abstract][Full Text] [Related]
2. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
4. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
Schulze K; Olive C; Ebensen T; Guzmán CA
Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
[TBL] [Abstract][Full Text] [Related]
5. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
[TBL] [Abstract][Full Text] [Related]
6. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
7. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
9. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
11. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
[TBL] [Abstract][Full Text] [Related]
12. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
13. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
Marasini N; Giddam AK; Khalil ZG; Hussein WM; Capon RJ; Batzloff MR; Good MF; Toth I; Skwarczynski M
Nanomedicine (Lond); 2016 Dec; 11(24):3223-3235. PubMed ID: 27830630
[TBL] [Abstract][Full Text] [Related]
14. Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
PLoS One; 2017; 12(4):e0175707. PubMed ID: 28414746
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
16. A dual-adjuvanting strategy for peptide-based subunit vaccines against group A Streptococcus: Lipidation and polyelectrolyte complexes.
Zhao L; Yang J; Nahar UJ; Khalil ZG; Capon RJ; Hussein WM; Skwarczynski M; Toth I
Bioorg Med Chem; 2020 Dec; 28(24):115823. PubMed ID: 33120079
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
[TBL] [Abstract][Full Text] [Related]
18. Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.
Marasini N; Ghaffar KA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Curr Drug Deliv; 2017; 14(5):701-708. PubMed ID: 27440071
[TBL] [Abstract][Full Text] [Related]
19. Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.
Chen X; Li N; Bi S; Wang X; Wang B
PLoS One; 2016; 11(12):e0168861. PubMed ID: 28030629
[TBL] [Abstract][Full Text] [Related]
20. Activity Relationship of Poly(ethylenimine)-Based Liposomes as Group A
Jin S; Zhang J; Nahar UJ; Huang W; Alharbi NA; Shalash AO; Koirala P; Yang J; Kiong JJE; Khalil ZG; Capon RJ; Stephenson RJ; Skwarczynski M; Toth I; Hussein WM
ACS Infect Dis; 2023 Aug; 9(8):1570-1581. PubMed ID: 37489053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
